Abstract
Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints.
MeSH Terms
Adult
Aged
Angiogenesis Inhibitors/therapeutic use
Brain Neoplasms/blood supply,complications,drug therapy
Glioma/blood supply,complications,drug therapy
Humans
Intestinal Perforation/chemically induced,drug therapy
Middle Aged
Neovascularization, Pathologic
Treatment Outcome
Chemicals
Angiogenesis Inhibitors
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Norden Andrew D
Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA. anorden@partners.org
Drappatz Jan
Ciampa Abigail Slate
Doherty Lisa
LaFrankie Debra Conrad
Kesari Santosh
Wen Patrick Y
References (14)
14 references, click to expand
-
Use of corticosteroids in neuro-oncology.
Anticancer Drugs. 1995 Feb;6(1):19-33
PMID: 7756680
-
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Gynecol Oncol. 2007 Apr;105(1):3-6
PMID: 17383545
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med. 2004 Jun 3;350(23):2335-42
PMID: 15175435
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007 Jan;11(1):83-95
PMID: 17222792
-
Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids.
Neurosurgery. 1993 Jul;33(1):40-3
PMID: 8355846
-
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
J Clin Oncol. 2005 Nov 1;23(31):8033-40
PMID: 16258101
-
Management of bevacizumab-associated bowel perforation: a case series and review of the literature.
Ann Oncol. 2008 Mar;19(3):577-82
PMID: 18024857
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
PMID: 17317837
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
J Clin Oncol. 1999 Aug;17(8):2572-8
PMID: 10561324
-
Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease.
Neurology. 1988 Mar;38(3):348-52
PMID: 3258062
-
Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Curr Surg. 2006 Sep-Oct;63(5):334-7
PMID: 16971205
-
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
Ann Surg Oncol. 2007 Jun;14(6):1860-9
PMID: 17356952
-
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
J Clin Oncol. 2006 Nov 20;24(33):5201-6
PMID: 17114652
-
Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions.
Ann Rheum Dis. 2004 May;63(5):588-90
PMID: 15082493